GT BIOPHARMA, INC. Accounts Payable
GT BIOPHARMA, INC. (GTBP) had Accounts Payable of $1.02 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-14
- 2026-06-30: Accounts Payable, Current $1.02M.
- 2026-03-31: Accounts Payable, Current $253.00K.
- 2025-12-31: Accounts Payable, Current $748.00K.
- 2025-09-30: Accounts Payable, Current $769.00K.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $1.02M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $253.00K 10-Q · filed 2026-05-15 |
| 2025-12-31 | $748.00K 10-Q · filed 2026-08-14 |
| 2025-09-30 | $769.00K 10-Q/A · filed 2026-03-06 |
| 2025-06-30 | $1.37M 10-Q/A · filed 2026-03-06 |
| 2025-03-31 | $2.38M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $3.85M 10-Q/A · filed 2026-03-06 |
| 2024-09-30 | $2.61M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $1.72M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $3.21M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $4.33M 10-K · filed 2025-02-21 |
| 2023-09-30 | $3.97M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $3.50M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $3.13M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $3.14M 10-K · filed 2024-03-26 |
| 2022-09-30 | $3.33M 10-Q · filed 2022-10-31 |
| 2022-06-30 | $7.26M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $8.11M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $8.19M 10-K · filed 2023-03-30 |
| 2021-09-30 | $2.80M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $1.50M 10-Q/A · filed 2021-12-29 |
| 2021-03-31 | $2.38M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $2.24M 10-K · filed 2022-03-28 |
| 2020-09-30 | $2.17M 10-Q · filed 2020-11-13 |
| 2020-06-30 | $2.00M 10-Q/A · filed 2020-08-18 |
| 2020-03-31 | $2.37M 10-Q · filed 2020-05-15 |
| 2019-12-31 | $1.94M 10-K · filed 2021-04-16 |
| 2019-09-30 | $1.72M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $1.71M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $1.90M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $1.76M 10-K · filed 2020-03-27 |
| 2018-09-30 | $2.25M 10-Q · filed 2018-11-14 |
| 2018-06-30 | $1.89M 10-Q · filed 2018-08-14 |
| 2018-03-31 | $1.83M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $2.55M 10-K · filed 2019-03-29 |
| 2017-09-30 | $2.71M 10-Q · filed 2017-11-14 |
| 2017-06-30 | $2.35M 10-Q · filed 2017-08-11 |
| 2017-03-31 | $2.06M 10-Q · filed 2017-04-28 |
| 2016-12-31 | $2.10M 10-K · filed 2018-03-01 |
| 2016-09-30 | $1.81M 10-Q/A · filed 2018-02-28 |
| 2016-06-30 | $1.57M 10-Q/A · filed 2018-02-28 |
| 2016-03-31 | $1.54M 10-Q/A · filed 2018-02-28 |
| 2015-12-31 | $893.00K 10-K/A · filed 2018-02-28 |
| 2015-09-30 | $968.00K 10-Q · filed 2015-11-13 |
| 2015-06-30 | $431.00K 10-Q · filed 2015-08-14 |
| 2015-03-31 | $256.00K 10-Q · filed 2015-05-14 |
| 2014-12-31 | $412.00K 10-K/A · filed 2018-02-28 |
| 2014-09-30 | $820.00K 10-Q · filed 2015-01-08 |
| 2014-06-30 | $925.00K 10-Q · filed 2015-01-08 |
| 2014-03-31 | $935.00K 10-Q · filed 2015-01-08 |
| 2013-12-31 | $940.00K 10-K · filed 2015-03-31 |
| 2013-09-30 | $935.00K 10-Q · filed 2014-12-17 |
| 2013-06-30 | $904.00K 10-Q · filed 2014-12-12 |
| 2013-03-31 | $883.00K 10-Q · filed 2014-12-10 |
| 2012-12-31 | $878.00K 10-K · filed 2015-01-08 |
| 2012-09-30 | $858.00K 10-Q · filed 2012-11-21 |
| 2012-06-30 | $813.00K 10-Q/A · filed 2012-09-13 |
| 2012-03-31 | $815.00K 10-Q · filed 2012-05-21 |
| 2011-12-31 | $806.00K 10-K · filed 2014-11-18 |
| 2011-09-30 | $974.00K 10-Q · filed 2011-11-21 |
| 2011-06-30 | $772.00K 10-Q/A · filed 2011-09-12 |
| 2010-12-31 | $625.00K 10-K · filed 2012-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |